Yang Zhou

Dr. Yang Zhou

Harbin Medical University Cancer Hospital

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
YZYanlin Zhu
Yanlin Zhu
XWXinxin Wang
Xinxin Wang
Feng LiliFeng Lili
Feng Lili
RZRuoxi Zhao
Ruoxi Zhao
CYCan Yu
Can Yu
Piaoping YangPiaoping Yang
Piaoping Yang
Pyroptosis, an immunogenic programmed cell death, could efficiently activate tumor immunogenicity and reprogram immunosuppressive microenvironment for boosting cancer immunotherapy. However, the overexpression of SLC7A11 promotes glutathione biosynthesis for maintaining redox balance and countering pyroptosis. Herein, we develop intermetallics modified with glucose oxidase (GOx) and soybean phospholipid (SP) as pyroptosis promoters (Pd2Sn@GOx-SP), that not only induce pyroptosis by cascade biocatalysis for remodeling tumor microenvironment and facilitating tumor cell immunogenicity, but also trigger disulfidptosis mediated by cystine accumulation to further promote tumor pyroptosis in female mice. Experiments and density functional theory calculations show that Pd2Sn nanorods with an intermediate size exhibit stronger photothermal and enzyme catalytic activity compared with the other three morphologies investigated. The peroxidase-mimic and oxidase-mimic activities of Pd2Sn cause potent reactive oxygen species (ROS) storms for triggering pyroptosis, which could be self-reinforced by photothermal effect, hydrogen peroxide supply accompanied by glycometabolism, and oxygen production from catalase-mimic activity of Pd2Sn. Moreover, the increase of NADP+/NADPH ratio induced by glucose starvation could pose excessive cystine accumulation and inhibit glutathione synthesis, which could cause disulfidptosis and further augment ROS-mediated pyroptosis, respectively. This two-pronged treatment strategy could represent an alternative therapeutic approach to expand anti-tumor immunotherapy.

25 November 2020 in Abdominal Radiology
Verified
Journal Article
Closed access
PDF file
JLJin Li
Jin Li
YZYang Zhou
Yang Zhou
XWXinxin Wang
Xinxin Wang
MZMeijuan Zhou
Meijuan Zhou
XCXi Chen
Xi Chen
KLKuan Luan
Kuan Luan

9 December 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
MZMeng Zhou
Meng Zhou
CZChunhui Zhang
Chunhui Zhang
JNJianhua Nie
Jianhua Nie
YSYajuan Sun
Yajuan Sun
YXYe Xu
Ye Xu
TZTongsen Zheng
Tongsen Zheng
Background: Precise evaluation of the efficacy of immunotherapy is critical in the effective management and treatment of advanced hepatocellular carcinoma (HCC). Therefore, the purpose of this study was to compare the response assessments achieved by different criteria and to evaluate the correlation between survival outcome and response assessment in HCC treated with programmed cell death protein 1 (PD-1) inhibitor.Methods: Fifty patients with advanced HCC treated with first-line PD-1 inhibitor with baseline and follow‐up CT images were analyzed. The patients were categorized into responders and nonresponders according to the criteria.Results: When the response assessments between RECIST 1.1 and mRECIST were compared, no statistically significant differences were observed. Overall response rate was 16% by RECIST 1.1 and iRECIST and was 24% by mRECIST. According to RECIST 1.1 and mRECIST, overall survival (OS) and progression-free survival (PFS) were not statistically different between the complete response (CR) and partial response (PR) groups and the stable disease (SD) and progressive disease (PD) groups. The OS and PFS were significantly different between responders and nonresponders according to mRECIST. The Cohen’s Kappa for RECIST 1.1, iRECIST, and mRECIST was 0.534, 0.438, and 0.363, respectively.Conclusion: The mRECIST criteria have a powerful ability to discriminate between responders and nonresponders and demonstrated significantly longer OS and PFS in responders than in nonresponders. However, mRECIST needs to be further improved in order for it to be widely used in the clinical evaluation of immunotherapy in HCC.

6 May 2020 in BMC Cancer
Verified
Journal Article
Open access
PDF file
STShuli Tang
Shuli Tang
LLLin Lin
Lin Lin
JCJianan Cheng
Jianan Cheng
JZJuan Zhao
Juan Zhao
QXQijia Xuan
Qijia Xuan
YZYanqiao Zhang
Yanqiao Zhang
Background: Chronic inflammation is considered as a hallmark of gastric cancer (GC) and plays a critical role in GC progression and metastasis. This study aimed to explore the prognostic values of preoperative fibrinogen-to-prealbumin ratio (FPR), fibrinogen-to-albumin ratio (FAR), and novel FPR-FAR-CEA (FFC) score in patients with GC undergoing gastrectomy. Methods: A total of 273 patients with resectable GC were included in this retrospective study. We performed Kaplan-Meier and Cox regression analyses to assess the prognostic role of preoperative FPR, FAR, and FFC score in patients with GC and analyze their relationships with clinicopathological features. Results: Receiver operating characteristic curve (ROC) analysis revealed that the optimal cutoff values for FPR and FAR were 0.0145 and 0.0784, respectively. The FFC score had a higher area under the ROC curve than FAR and CEA. Elevated FPR (≥ 0.0145) and FAR (≥ 0.0784) were significantly associated with old age, large tumor size, tumor invasion depth, lymph nodes metastasis, advanced TNM stage, large Borrmann type, and anemia status. Kaplan-Meier analysis showed that high FPR, FAR, and FFC score were related to poor survival. Multivariate analyses indicated that FPR, FFC score, TNM stage, and tumor size were significant independent factors for survival. Conclusions: Preoperative FPR and FFC score could be used as prospective noninvasive prognostic biomarkers for resectable GC.

19 June 2019 in Cancer Imaging
Verified
Journal Article
Open access
PDF file
YZYang Zhou
Yang Zhou
HZHongxia Zhang
Hongxia Zhang
XZXiu-Shi Zhang
Xiu-Shi Zhang
YSYun-Feng Sun
Yun-Feng Sun
KHKuang-Bang He
Kuang-Bang He
ZKZi-Xiang Kuai
Zi-Xiang Kuai
Preoperative chemotherapy is becoming standard therapy for liver metastasis from colorectal cancer, so early assessment of treatment response is crucial to make a reasonable therapeutic regimen and avoid overtreatment, especially for patients with severe side effects. The role of three non-mono-exponential diffusion models, such as the kurtosis model, the stretched exponential model and the statistical model, were explored in this study to early assess the response to chemotherapy in patients with liver metastasis from colorectal cancer. Thirty-three patients diagnosed as colorectal liver metastasis were evaluated in this study. Diffusion-weighted images with b values (0, 200, 500, 1000, 1500, 2000 s/mm2) were acquired at 3.0 T. The parameters (ADCk, K, DDC,α, Ds and σ) were derived from three non-mono-exponential models (the kurtosis, stretched exponential and statistical models) as well as their corresponding percentage changes before and after chemotherapy. The difference in above parameters between the response and non-response groups were analyzed with independent-samples T-test (normality) and Mann–Whitney U-test (non-normality). Meanwhile, receiver operating characteristic curve (ROC) analyses were performed to assess the response to chemotherapy. Significantly lower values of K (the kurtosis coefficient derived from the kurtosis model) and σ (the width of diffusion coefficient distribution in the statistical model) (P < 0.05) were observed in the respond group before treatment, as well as higher ΔK and Δσ values (P < 0.05) after the first cycle of chemotherapy were also found compared with the non-respond group. ROC analyses showed the K value acquired before treatment had the highest diagnostic performance (0.746) in distinguishing responders from non-responders. Furthermore, the high sensitivity (100%) and accuracy (76.3%) from the K value before treatment was found in assessing the response of colorectal liver metastasis to chemotherapy. The non-mono-exponential diffusion models may be able to predict early response to chemotherapy in patients with colorectal liver metastasis.

1 December 2020 in European Journal of Radiology
Verified
Journal Article
Closed access
XWXinxin Wang
Xinxin Wang
ZZZiqian Zhang
Ziqian Zhang
XZXueyan Zhou
Xueyan Zhou
YZYuning Zhang
Yuning Zhang
JZJiamin Zhou
Jiamin Zhou
YZYang Zhou
Yang Zhou